Treatment of inflammatory bowel disease with azathioprine: How to use it in 1999

Acta Gastro-Enterologica Belgica

Volumn 62, Issue 4, 1999, Pages 437-439

  Louis, Edouard ^a   Belaiche, J ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE;

BONE MARROW TOXICITY; CONFERENCE PAPER; CROHN DISEASE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; OPPORTUNISTIC INFECTION; PANCREATITIS; RELAPSE; TREATMENT OUTCOME;

6-MERCAPTOPURINE; AZATHIOPRINE; BONE MARROW; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRODRUGS; RECURRENCE;

EID: 0033396011     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. SUMMERS R.W., SWITZ D.M., SESSIONS J.T., BECKTEL J.M., BEST W.R., KERN JR F. et al. National cooperative Crohn's disease study : results of drug treatment. Gastroenterology, 1979, 77 : 847-869.
2. PEARSON D.C., MAY G.R., FICK G.H., SUTHERLAND L.R. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann. Intern. Med., 1995, 123 : 132-142.
3. PRESENT D.H., KORELITZ B.I., WISCH N., GLASS J.L., SACHAR D.B., PASTERNACK B.S. Treatment of Crohn's disease with 6-mercaptopurine : a long-term, randomized, double-blind study. N. Engl. J. Med., 1980, 302 : 981-987.
4. CONNELL W.R., KAMM M.A., DICKSON M., BALKWILL A.M., RITCHIE J.K., LENNARD-JONES J.E. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet, 1994, 343 : 1249-1252.
5. BLONDEL-KUCHARSKI F., CHIRCOP C., MARQUIS P., COLOMBEL J.F., GENDRE J.P. and the GETAID Qualité de vie au cours de la maladie de Crohn. Etude prospective longitudinale de 231 patients. Gastroenterol. Clin. Biol., 1999, 23 : A85.
6. SANDBORN W.J., VAN OS E., ZINS B.J., TREMAINE W.J., MAYS D.C., LIPSKY J.J. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease.
7. SANDBORN W.J., TREMAINE W.J., WOLF D.C., TARGAN S.R., SNINSKY C.A., SUTHERLAND L.R., HANAUER S.B., MCDONALD J.W.D., MAYS D.C., LIPSKY J.J., KLEOUDIS C., MURDOCK R.H. A randomized, double-blind, placebo-controlled, multicenter trial of intravenous azathioprine loading to decrease the time to response in steroid-refractory Crohn's disease. Digestion, 1998, 59 : GaPP0045.
8. LOUIS E., DUPONT P., DEPAUW A., CROES F., DEMOLlN G., BELAICHE J. Rapide anti-inflammatory effect of high dose azathioprine in inflammatory bowel disease : an in vitro study. Gastroenterology, 1998, 114 : G4206.
9. BARBE L., MARTEAU P., LÉMANN M., BOUHNIK Y., ALLEZ M., COFFIN B., BONNETT J., MESSING B., RAMBAUD J.C., MODIGLIANI R. Dose raising of azathioprine beyond 2.5 mg/Kg/day in Crohn's disease patients who fail to improve with a standard dose. Gastroenterology, 1998, 114 : G3794.
10. COLONNA T., KORELITZ B.I. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am. J. Gastroenterol., 1994, 89 : 362-366.
11. CUFFARI C., THÉORÊT Y., LATOUR S., SEIDMAN G. 6-mercaptopurine metabolism in Crohn's disease : correlation with efficacy and toxicity. Gut, 1996, 39 : 401-406.
12. BERGAN S., RUGSTAD H.E., BENTDAL O., SODAL G., HARTMANN A., LEIVESTAD T., STOKKE O. Monitored high-dose azathioprine treatment reduces acute rejection episodes after renal transplantation. Transplantation, 1998, 66 : 334-339.
13. LENNARD L., LILLEYMAN J.S., VAN LOON J., WEINSHILBOUM R.M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet, 1990, 336 : 225-229.
14. LENNARD L., REES L.A., LILLEYMAN J.S., MADDOCKS J.L. Childhood leukaemia : a relationship between intracellular 6-mercaptopurine metabolises and neutropenia. Br. J. Clin. Pharmacol., 1983, 16 : 359-363.
15. O'DONOGHUE D.P., DAWSON A.M., POWEL-TUCK K., BOWN R.L. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet, 1978, ii : 944-946.
16. KORELITZ B.I., ADLER D.J., MENDELSOHN R.A., SACKNOFF A. Long-term experience with 6-mercaptopurine in the treatment of Crohn's disease. Am. J. Gastroenterol., 1993, 88 : 1198-1205.
17. BOUHNIK Y., LÉMANN M., MARY J.-Y., SCEMAMA G., TAÏ R., MATUCHANSKY C., MODIGLIANI R., RAMBAUD J.-C. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet, 1996, 347 : 215-219.
18. CONNELL W.R., KAMM M.A., RITCHIE J.K., LENNARD-JONES J.E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease : 27 years of experience. Gut, 1993, 34 : 1081-1085.
19. KRYNETSKI E.Y., TAI H.L., YATES C.R., FESSING M.Y., LOENNECHEN T., SCHUETZ J.D., REELING M.V., EVANS W.E. Genetic polymorphism of thiopurine S-methyltransferase : clinical importance and molecular mechanisms. Pharmacogenetics, 1996, 6 : 279-290.
20. BERGAN S. Optimisation of azathioprine immunosuppression after organ transplantation by pharmacological measurements. BioDrugs, 1997, 8 : 446-456.
21. BERGAN S., RUGSTAD H.E., KLEMETSDAL B., GIVERHAUG T., BENTDAL O., SODAL G., HARTMANN A., AARBAKKE J., STOKKE O. Possibilities for therapeutic drug monitoring of azathioprine : 6-thioguanine nucleotide concentrations and thiopurine methyltransferase activity in red blood cells. Ther. Drug Monit., 1997, 19 : 318-326.
22. SZUMLANSKI C.L., WEINSHILBOUM R.M. Sulfasalazine inhibition of thiopurine methyltransferase : possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br. J. Clin. Pharmac., 1995, 39 : 456-459.
23. CHOCAIR P.R., DULEY J.A., SIMMONDS H.A. The importance of thiopurine methyltransferase activity for the use of azathioprine in kidney transplant recipients. Transplantation, 1992, 53 : 1051-1056.
24. EVANS W.E., HOMER M., CHU Y.Q., KALWINSKY D., ROBERTS W.M. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyl-transferase deficient child with acute lymphocytic leukemia. J. Pediatr., 1991, 119 : 985-989.
25. PRESENT D.H., MELTZER S.J., KRUMHOLTZ M.P., WOLKE A., KORELITZ B.I. 6-Mercaptopurine in the managment of inflammatory bowel disease : short-and long-term toxicity. Ann. Intern. Med., 1989, 111 : 641-649.
26. LÉMAN M., BOUHNIK Y., KMIECIAK-LE CORGUILLE M., BONNET J., COFFIN B., MARTEAU P., BITOUN P., MESSING B., JIAN R., MATUCHANSKY C., MODIGLIANI R., RAMBAUD J.C. Treatment of Crohn's disease (CD) with 6-mercaptopurine (6-MP) in patients intolerant to azathioprine (AZA). Gastroenterology, 1997, 112 : A1025.